DENISON, TX / ACCESSWIRE / March 11, 2020 / PreCheck Health Services, Inc. (OTCPINK:HLTY), a provider of medical screening devices which provide data to assist physicians in preventing and treating chronic diseases, announced today it has entered into the $33 billion global infectious disease diagnostic testing sector with an exclusive agreement with a U.S. based molecular diagnostics company, to distribute its coronavirus 2019 (COVID 19) test which currently detects both strains of the COVID 19 virus and all of its products in Russia. PreCheck has ordered an initial 7,500 COVID 19 test kits and now will be registering the product for Russia.
Justin Anderson, Chief Executive Officer of PreCheck Health Services, commented, “We’re excited to enter into this agreement which launches PreCheck into the global infectious disease diagnostic market. Although we are focused currently on the COVID 19 test to address the global crisis, we also look forward to leveraging the opportunity with all of our partner’s products, to maximize shareholder value.”
Further information is available in the Company’s regulatory filing, which can be accessed at www.sec.gov.
About PreCheck Health Services, Inc.
PreCheck Health Services, Inc. provides a medical screening service, which makes early detection and monitoring of chronic diseases easy and cost-effective for patients and doctors. The Company distributes a non-invasive medical screening device which screens for biomarkers, which are precursors to chronic disease. The device assesses sudomotor function, cardiac autonomic function, and endothelial function and measures the ankle brachial indices. In addition, the device calculates a patented cardiometabolic risk score based on these assessments and measurements, body composition, vital signs, and fitness markers. Cardiometabolic risk refers to the chance of having or developing diabetes, heart disease, or stroke. This device is targeted at the rapidly growing $139 billion global preventive healthcare technologies and services market, according to Grand View Research. The Company has an experienced management team with several decades of combined experience in medical testing services and medical device sales. The technology has been developed to address the growing mandates from Medicare, Medicaid, and insurance companies regarding early detection and prevention of chronic diseases.
PreCheck Health Services’ offering is based on the Company’s PC8B, an FDA-cleared and patented medical screening device, which performs a range of screening tests generally covered and reimbursed by Medicare, Medicaid, and most insurance companies. The non-invasive diagnostic tests are performed simultaneously, collectively taking under 10 minutes to perform and screening patients for multiple risk factors underlying certain chronic ailments, such as insulin resistance, cardiovascular disease (including PAD), endothelia dysfunction, digestive problems, and fatigue. The PC8B’s software helps the physician recommend a treatment plan for the patient.
Disclaimer for Forward-Looking Information
Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including our ability to obtain substantial funding required for our operations; our ability to market our product to physicians, our ability to generate a gross margin from any sales we may make; our dependence upon a sole suppliers for our products and our reliance of the supplier to protect its intellectual property incorporated in our product; our ability to obtain rights to and to market successfully market products, our ability to develop the business of these businesses, as well as other risks contained in “Forward Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form 10-K for the year ended December 31, 2018 and in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in its Form 10-Q for the quarter ended September 30, 2019, and any information contained in any other filings we make with the SEC.
Contact:
Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
SOURCE: PreCheck Health Services, Inc.
View source version on accesswire.com:
https://www.accesswire.com/580067/PreCheck-Health-to-Exclusively-Distribute-Coronavirus-COVID-19-Test-in-Russia-for-a-US-Based-Molecular-Diagnostics-Company
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext…
BEIJING--(BUSINESS WIRE)--Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered…
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF…
SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO),…
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology…
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX,…